ArticleThe Pan African medical journal2025
Non-exanthematous mpox and the implications on response measures during outbreaks.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In 2024, mpox was declared a public health emergency. Several response measures have since been implemented by health authorities in the affected countries to control the outbreak. Our perspective was triggered by an article in the special issue on the surge of mpox in Africa that highlighted rashless or non-exanthematous presentations of mpox in Nigeria. Although these have been previously highlighted, especially during the global outbreak in 2022, the contribution of these factors to the general outbreak dynamics remains poorly understood. We reflect on the possible implications of this outbreak and strategies to address it in the context of a newer clade 1b responsible for the current upsurge, where no prevalence studies of rashless mpox have been done. Using our experiences, we also discuss how diagnostic expectations centred on the presence of rash may hinder timely detection, response, and reporting. Moreover, current outbreak situation reports do not disaggregate cases by symptom profile (for example, rash-presenting versus rashless), a gap that undermines a comprehensive understanding of the actual burden of mpox. Finally, we analyse the potential implications of undetected spread, surveillance, vaccination strategies and risk communication and behavioural change practices, to help break the chains of transmission that might have been missed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.